Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report

An artist in residence (she can afford)

Jun 24, 2019

Latest Episodes

Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Tech
Download
HTML Embed
HTML EMBED
Click to Copy
Make Me Smart with Kai and Molly
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace Morning Report
Download
HTML Embed
HTML EMBED
Click to Copy
Download
HTML Embed
HTML EMBED
Click to Copy
Marketplace

Deals aimed at reining in costs of cancer drugs show promise

Dan Gorenstein Jun 6, 2016
Share Now on:
HTML EMBED:
COPY
Dr. Julie Brahmer (R) and Katie Thornton review PET (Positron Emission Tomography) scans of a patient being treated at the Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. 
Win McNamee/Getty Images

Cancer drug costs have gone up 72 percent over the last five years, to about $15.9 billion. It’s one sobering reality oncologists are facing at one of their big annual meetings this week in Chicago. 

But one new effort is showing early signs of reining in those costs. A company that specializes in buying prescription drugs for large employers and health insurers is cutting new types of deals with pharmaceutical companies.

“We have a handful of really innovative, forward-thinking companies willing to say, ‘If my drug doesn’t work well, I shouldn’t be paid as much,'” said Express Scripts Chief Medical Officer Steve Miller.

Express Scripts has contracts with six to 10 manufacturers that tie price to a drug’s performance.

In just the first 10 weeks of the program, doctors are starting to prescribe these drugs over others.

The fact that it’s already been taken up by so many manufacturers, but also by so many physicians, tells you the power of this idea,”said University of Chicago economist Rena Conti.

This approach could slow how much we spend on the newest and most expensive cancer treatments. Until now, the manufacturer has had the upper hand when a new drug comes to market. Conti said these value-based deals will force drug makers to prove their products work if they want a premium price. 

If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air.  But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.

Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.

When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.